Seagen, A Wholly Owned Subsidiary Of Pfizer

This study is testing whether an experimental drug called tisotumab vedotin, given alone or with other cancer drugs, can help control advanced solid tumors. It enrolled 352 people with advanced colorectal, lung, pancreatic, or head and neck cancers that had stopped responding to …

This study is testing whether adding the pill tucatinib to two standard injected drugs (trastuzumab and pertuzumab) works better to control advanced HER2-positive breast cancer that has spread. It involves 654 people whose cancer responded to initial treatment and is now in a 'ma…

This early-stage study is testing a new drug called PF-08046052/SGN-EGFRd2 in people with advanced solid tumors that have spread or cannot be removed by surgery. The main goal is to find the safest dose and understand side effects in 65 participants with specific cancers includin…

This large, late-stage study is comparing an experimental targeted drug called sigvotatug vedotin against standard chemotherapy (docetaxel) for adults with advanced non-small cell lung cancer that has worsened after initial treatment. The trial aims to see if the new drug helps p…

This large, late-stage study is comparing a new two-drug combination (disitamab vedotin plus pembrolizumab) against standard chemotherapy for people with advanced bladder cancer that has spread. The goal is to see if the new combination works better to control the cancer and help…

This is an early-stage study testing a new experimental drug called SGN-MesoC2 in people with advanced solid tumors that have come back or stopped responding to standard treatments. The main goal is to find a safe dose and see how the body handles the drug. The drug is designed t…

This is the first study testing a new experimental drug called PF-08046044/SGN-35C in people with advanced lymphoma that has returned or stopped responding to standard treatments. The trial will enroll 57 adults with specific types of lymphoma to determine the safest dose, unders…

This is an early-stage study to test the safety and find the right dose of a new drug called PF-08046049/SGN-BB228. It is for adults with advanced solid tumors, including melanoma, lung, colorectal, pancreatic cancer, or mesothelioma, that have stopped responding to standard trea…

This study is testing whether adding a drug called tucatinib to standard cancer treatments is safe and effective for people with HER2-positive cancers of the digestive system, like stomach, colon, and gallbladder cancers. It involves about 40 participants who have advanced cancer…

This study is testing whether the drugs tucatinib and trastuzumab can help control advanced solid tumors that have specific changes in a protein called HER2. It is for adults with cancers like lung, cervical, or uterine cancer that have spread or cannot be removed by surgery, and…

This study is testing if adding a pill called tucatinib to a standard breast cancer drug (T-DM1) works better to control advanced HER2-positive breast cancer. It is for people whose cancer has spread or cannot be removed by surgery and has worsened after prior treatment. About 46…

This study is for people with an aggressive type of blood cancer called DLBCL that has returned or not responded to at least two prior treatments. It tests whether adding a drug called brentuximab vedotin to the standard two-drug therapy (lenalidomide and rituximab) helps patient…

This study is testing an experimental drug called disitamab vedotin for adults with advanced or metastatic solid tumors that have a specific marker called HER2. The trial includes people with head and neck, lung, ovarian, or endometrial cancers who have already tried other treatm…

This trial is testing a new drug called tisotumab vedotin for women with advanced cervical cancer that has come back or spread. The study will see how safe the drug is when given alone or combined with other cancer medicines, and if it helps shrink tumors. It is for women who hav…